Nuvectis Pharma, Inc.
NVCT
$18.96
-$0.27-1.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.51M | 2.15M | 2.53M | 2.02M | 2.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.20M | 6.26M | 7.62M | 7.79M | 6.60M |
| Operating Income | -7.20M | -6.26M | -7.62M | -7.79M | -6.60M |
| Income Before Tax | -7.02M | -6.05M | -7.31M | -7.46M | -6.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.02M | -6.05M | -7.31M | -7.46M | -6.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.02M | -6.05M | -7.31M | -7.46M | -6.33M |
| EBIT | -7.20M | -6.26M | -7.62M | -7.79M | -6.60M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.30 | -0.26 | -0.32 | -0.44 | -0.30 |
| Normalized Basic EPS | -0.19 | -0.16 | -0.20 | -0.21 | -0.19 |
| EPS Diluted | -0.30 | -0.26 | -0.32 | -0.44 | -0.30 |
| Normalized Diluted EPS | -0.19 | -0.16 | -0.20 | -0.21 | -0.19 |
| Average Basic Shares Outstanding | 23.48M | 23.41M | 23.20M | 22.72M | 21.37M |
| Average Diluted Shares Outstanding | 23.48M | 23.41M | 23.20M | 22.72M | 21.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |